Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 12/20 | 0.68 |
| ▸ | SRD5A1 | P18405 | 5/20 | 0.67 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8585490 | 0.92 | SRD5A2 (0.66) | SRD5A2SRD5A1 | |
| SCHEMBL8908689 | 0.92 | SRD5A2 (0.66) | SRD5A2SRD5A1 | |
| SCHEMBL8907905 | 0.92 | SRD5A2 (0.66) | SRD5A2SRD5A1 | |
| SCHEMBL8908115 | 0.88 | SRD5A2 (0.63) | SRD5A2SRD5A1ESR1ARESR2 | |
| SCHEMBL8631697 | 0.87 | SRD5A2 (0.71) | SRD5A2SRD5A1 | |
| SCHEMBL8908714 | 0.87 | SRD5A2 (0.67) | SRD5A2SRD5A1ESR1ARESR2 | |
| SCHEMBL8163423 | 0.87 | SRD5A2 (0.70) | SRD5A2SRD5A1ESR1ARESR2 | |
| SCHEMBL29655549 | 0.87 | SRD5A2 (0.70) | SRD5A2SRD5A1ESR1ARESR2 | |
| SCHEMBL8163428 | 0.87 | SRD5A2 (0.70) | SRD5A2SRD5A1ESR1ARESR2 | |
| SCHEMBL8994125 | 0.86 | SRD5A2 (0.60) | SRD5A2SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5641765-A | TREATS PROSTATIC ADENOCARCINOMA, BENIGN PROSTATE HYPERTROPHY; ANTAGONSIT, ANTAGONISM | SMITHKLINE BEECHAM CORPORATION (US) | 1997-06-24 | — | — | US | claimed |
| EP-0669932-A4 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE. | SMITHKLINE BEECHAM CORP (US) | 1995-10-25 | — | — | EP | claimed |
| EP-0669932-A1 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-09-06 | — | — | EP | claimed |
| WO-1994011386-A1 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1994-05-26 | — | — | WO | claimed |
| US-5641765-A | TREATS PROSTATIC ADENOCARCINOMA, BENIGN PROSTATE HYPERTROPHY; ANTAGONSIT, ANTAGONISM | SMITHKLINE BEECHAM CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| US-5641877-A | 17-α and 17-β substituted acyl-3-carboxy-3, 5-dienes and use in inhibiting 5-α-reductase | SMITHKLINE BEECHAM CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0669932-A4 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE. | SMITHKLINE BEECHAM CORP (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0669932-A1 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994011386-A1 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |